Alan Randall Steinberg sits on the Board of Directors of UCLA’s Jonsson Cancer Center Foundation, which raises research funding for UCLA's Jonsson Comprehensive Cancer Center.
In a recent release, Jonsson Comprehensive Cancer Center announced it has received a $1 million grant from the National Cancer Institute’s Small Business Innovation Research program to support the preclinical safety research on a progressive lung cancer treatment, hastening the potential advance into clinical trials. The new treatment combines nanotechnology and immunotherapy to transmit treatment agents while reducing hazardous side effects and better protecting healthy tissue. Through this approach, biological particles, known as vaults, are used to deliver the immunotherapy agent directly to the tumor cells. The researchers working on the treatment discovered the utility of vaults more than 15 years ago and since then have being striving to integrate “vault drug delivery technology” into modern medical practice. The researchers expect one specific treatment, the CCL21-vault, to be the first to reach the clinical trial stage.
0 Comments
|
AuthorAlan Randall Steinberg is a Principal at The Valence Group, Inc., where he focuses on corporate communications and public affairs. In this capacity, Alan Randall Steinberg develops and implements strategic media relations and public affairs plans, creates marketing materials, and writes bylined opinion pieces for the company’s clients, which include law firms, wealth management companies, and nonprofit organizations. Archives
November 2014
Categories
All
|